Evaluating Whole Fruit Feijoa Powder for Type 2 Diabetes Risk Prevention: A Randomised Controlled Trial
Authors' conclusion
In adults with overweight (predominantly obesity) and prediabetes, Fx supplementation may enhance blood pressure improvement achieved through BW loss.
Study context
- Population
- Adults with overweight (predominantly obesity) and prediabetes undergoing 2 months of LED-induced weight loss followed by 4 months of weight loss maintenance advice
- Participants
- 97 adults
- Comparison
- Whole fruit feijoa powder (Fx) 1150 mg/day vs placebo, with LED-induced weight loss
- Fxn = 48
- Placebon = 49reference
- Primary endpoint
- BW and FPG
- Follow-up
- 6 months
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
As reported in the abstract
Body weight (BW) decreased in both groups during 2-month LED, with gradual upward trajectory over subsequent 4 months
time0-6m: p < 0.001
Fasting plasma glucose (FPG) followed the weight loss trajectory in both groups
time0-6m: p < 0.001
Secondary outcomes
| Outcome | P value |
|---|---|
| SBP · 6 monthsFx vs Placebo | treatment×time0-6m: p = 0.01 |
| SBP · 6 monthsFx vs Placebo · SBP lower in Fx than Placebo at M4 and M6 | P < 0.05, both |
Diastolic blood pressure (BP) · 6 months
- Diastolic BP did not decline differently between treatments
Original publication
Evaluating Whole Fruit Feijoa Powder for Type 2 Diabetes Risk Prevention: A Randomised Controlled Trial. Diabetes Obes Metab. Published 1 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →